Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
CFA001-C01 | Calibrator | 20 μg |
CFA001-C02 | IFN-γ Beads | 96 tests |
CFA001-C03 | 2× Assay Buffer | 40 mL |
CFA001-C04 | 10× Wash Buffer | 10 mL |
CFA001-C05 | Detection antibody | 1 mL |
CFA001-C06 | SA-PE | 40 μg |
CFA001-C08 | 96-well Sealing film | 2 pieces |
CFA001-C09 | APC Positive Control | 500 μL |
CFA001-C10 | PE Positive Control | 500 μL |
Human IFN-γ FCM Kit (Flow Cytometry Assay) is a bead-based immunoassay capable of measuring human interferon-γ (IFN-γ) in serum, plasma, and cell culture supernatant samples.
It is for research use only.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
For each experiment, each 96-well V-bottom plate needs to set the standard curve. The minimum detectable concentration of CFA001-C02 is less than 2.0 pg/mL.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadi-05 | Cadi-05 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid) | Immuvac, Leprovac, Mycidac-C | India | Carcinoma, Non-Small-Cell Lung; Leprosy | null | 1998-01-01 | Leprosy; Carcinoma, Non-Small-Cell Lung | Details |
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
Emapalumab | NI-0501 | Approved | Novimmune Sa | Gamifant | Mainland China | Lymphohistiocytosis, Hemophagocytic | Sobi Pharmaceutical (Guangzhou) Co Ltd | 2018-11-20 | Macrophage Activation Syndrome; Still's Disease, Adult-Onset; Rare Diseases; Arthritis, Juvenile; Immune System Diseases; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Multiple Sclerosis; Crohn Disease | Details |
AMG-811 | AMG-811 | Amgen Inc | Details | ||
Tadekinig alfa (AB2 Bio) | Phase 3 Clinical | Ab2 Bio Ltd | Macrophage Activation Syndrome; Cytokine Release Syndrome; Lymphohistiocytosis, Hemophagocytic | Details | |
Recombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products) | Phase 1 Clinical | Guangzhou Dabo Biological Products Co Ltd | Liver Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
YH-32367 | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
SP-002 | SP-002; ASN-002; TG-1042 | Phase 2 Clinical | Solid tumours; Lymphoma, B-Cell; Carcinoma, Basal Cell; Skin Neoplasms; Basal Cell Nevus Syndrome; Melanoma | Details | |
EI-001 | EI-001 | Phase 1 Clinical | Elixiron Immunotherapeutics Inc | Vitiligo | Details |
KIO-100 | PP-001; KIO-101; KIO-100 | Phase 2 Clinical | 4sc Ag | Dry Eye Syndromes; Uveitis; Xerophthalmia; Keratoconjunctivitis | Details |
PDS-0101 | PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101 | Phase 2 Clinical | Pds Biotechnology Corporation, Merck Serono | Head and Neck Neoplasms; Anus Neoplasms; Papillomavirus Infections; Vulvar Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.